Eculizumab for Atypical Hemolytic-Uremic Syndrome.

被引：277
|
作者：
Nuernberger, Jens [1 ]
Witzke, Oliver [1 ]
Saez, Anabelle Opazo [1 ]
Vester, Udo [1 ]
Baba, Hideo Andreas [1 ]
Kribben, Andreas [1 ]
Zimmerhackl, Lothar Bernd [2 ]
Janecke, Andreas R. [2 ]
Nagel, Mato [3 ]
Kirschfink, Michael [4 ]
机构：
[1] Univ Duisburg Essen, D-45122 Essen, Germany
[2] Innsbruck Med Univ, A-6020 Innsbruck, Austria
[3] Ctr Nephrol & Metab Disorders, D-02943 Weisswasser, Germany
[4] Univ Heidelberg, D-69120 Heidelberg, Germany
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2009年 / 360卷 / 05期
关键词：
D O I：
10.1056/NEJMc0808527
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：542 / 544
页数：3
相关论文
共 50 条
  • [1] Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome.
    Gruppo, Ralph A.
    Rother, Russell P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (05): : 544 - 546
  • [2] Eculizumab in Atypical Hemolytic-Uremic Syndrome
    Kistler, Andreas D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14): : 1378 - 1378
  • [3] Prophylactic Eculizumab after Renal Transplantationin Atypical Hemolytic-Uremic Syndrome.
    Zimmerhackl, Lothar Bernd
    Hofer, Johannes
    Cortina, Gerard
    Mark, Walter
    Wuerzner, Reinhard
    Jungraithmayr, Therese C.
    Khursigara, Gus
    Kliche, Kay O.
    Radauer, Wolfgang
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (18): : 1746 - 1748
  • [4] Eculizumab in Atypical Hemolytic-Uremic Syndrome Reply
    Legendre, Christophe M.
    Licht, Christoph
    Loirat, Chantal
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14): : 1379 - 1380
  • [5] Eculizumab for atypical hemolytic-uremic syndrome. How long should we maintain it?
    Naranjo Munoz, Javier
    Garcia Garcia-Doncel, Ana
    Montero Escobar, Maria Elisa
    Villanego Fernandez, Florentino
    Millan Ortega, Irene
    Ceballos Guerrero, Manuel
    NEFROLOGIA, 2019, 39 (04): : 440 - 442
  • [6] More on Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome
    Shin, Jae Il
    Lee, Jae Seung
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20): : 2142 - 2143
  • [7] More on Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome Reply
    Gruppo, Ralph A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20): : 2143 - 2143
  • [8] Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
    Legendre, C. M.
    Licht, C.
    Muus, P.
    Greenbaum, L. A.
    Babu, S.
    Bedrosian, C.
    Bingham, C.
    Cohen, D. J.
    Delmas, Y.
    Douglas, K.
    Eitner, F.
    Feldkamp, T.
    Fouque, D.
    Furman, R. R.
    Gaber, O.
    Herthelius, M.
    Hourmant, M.
    Karpman, D.
    Lebranchu, Y.
    Mariat, C.
    Menne, J.
    Moulin, B.
    Nuernberger, J.
    Ogawa, M.
    Remuzzi, G.
    Richard, T.
    Sberro-Soussan, R.
    Severino, B.
    Sheerin, N. S.
    Trivelli, A.
    Zimmerhackl, L. B.
    Goodship, T.
    Loirat, C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (23): : 2169 - 2181
  • [9] Gemcitabine-Associated Atypical Hemolytic-Uremic Syndrome Treated with Eculizumab
    Plesa, A.
    Suarez, A.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2020, 73 (01): : 77 - 78
  • [10] Nephromegaly in an Infant with Atypical Hemolytic-Uremic Syndrome Resolving Successfully with Eculizumab
    Kumar, Gurinder
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2018, 29 (04) : 967 - 970
12345